Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.

@article{Talbot2010TumorSI,
  title={Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.},
  author={Denis Talbot and Malcolm Ranson and Joanna Davies and Michael Lahn and Sophie Callies and Valerie A M Andre and Sunil Kadam and M Catherine Burgess and Christopher A. Slapak and Anna L Olsen and Peter J McHugh and Johann S. de Bono and Julian R Matthews and Azeem Saleem and Patricia Price},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 24},
  pages={6150-8}
}
PURPOSE Enhanced tumor cell survival through expression of inhibitors of apoptosis (IAP) is a hallmark of cancer. Survivin, an IAP absent from most normal tissues, is overexpressed in many malignancies and associated with a poorer prognosis. We report the first-in-human dose study of LY2181308, a second-generation antisense oligonucleotide (ASO) directed against survivin mRNA. PATIENTS AND METHODS A dose-escalation study evaluating the safety, pharmacokinetics, and pharmacodynamics of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Survivin-Based Treatment Strategies for Squamous Cell Carcinoma

International journal of molecular sciences • 2018
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 35 references

A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

Clinical colorectal cancer • 2004
View 8 Excerpts
Highly Influenced

Tumor survivin is downregulated by the antisense oligonucleotide LY 2181308 : a proof - of - concept , first - inhuman dose study

DC Talbot, M Ranson, J Davies, M Lahn, S Callies
Clin Cancer Res • 2010

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 2 Excerpts

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…